The Etiological Role of Sars-Cov-2 On Hematologic Diseases

Aim: The aim of this study is to evaluate the association between hematologic diseases and SARS-CoV-2
infection in patients who have been been diagnosed with a hemat ologic disease after COVID-19 infection.
Patients and Methods: The ones who had a previously history of COVID-19 infection among the patients
diagnosed with any malign or autoimmune hematologic disease were evaluated between April 1, 2020 – April
1, 2021, retrospectively. The Patients who had the COVID-19 infection and the patients who had not were
compared.
Results: Twenty-four (7.8%) patients of 305 newly diagnosed who had a previously history of COVID-19
infection were determined. The most common diagnosis was non-Hodgkin Lymphoma in both of the groups.
Although it was not statistically significant, frequency of NHL and aggressive NHL were most common in
the patients with history of COVID-19 (25.1% vs 23.1%; p=0.143 and 66.6% vs 56.9%, p=0.094). The basic
hematologic parameters were similar between the two groups. The median time between COVID-19 infection
and the hematologic diagnosis was 4.1 (0.6-11.8) month; the minimum duration was in the patient with
Immune Thrombocytopenic Purpura and the maximum was the one with Multiple Myeloma. The median time
up until the diagnosis was longer in the malign group (4.5 vs 2.5 months; p=0.070).
Conclusions: As a result of the study, it has been emphasized that COVID-19 may have an etiological factor
for malign and hematologic diseases with autoimmune pathogenesi s.